HER-2 testing in breast cancer using parallel tissue-based methods. - Wikidata - awgldk - TriplyDB

HER-2 testing in breast cancer using parallel tissue-based methods.

HER-2 testing in breast cancer using parallel tissue-based methods.

http://www.wikidata.org/entity/Q47685189

about

Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis HER2 expression in cervical cancer as a potential therapeutic target Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer Utilization of genomic signatures to identify phenotype-specific drugs Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers.Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status.Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.Utilization of HER2 genetic testing in a multi-institutional observational study.Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study.ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.Understanding the implications of the breast cancer pathology report: a case study.A pan-cancer proteomic perspective on The Cancer Genome Atlas.Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo Synthesis and Characterization of Anti-HER2 Antibody Conjugated CdSe/CdZnS Quantum Dots for Fluorescence Imaging of Breast Cancer Cells.A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas Testing for HER2 in Breast Cancer: A Continuing Evolution.The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases.Development of peptide nucleic acid probes for detection of the HER2 oncogene Role of activated Rac1/Cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Genomic testing and therapies for breast cancer in clinical practice.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors Quality assessment of HER2 testing by monitoring of positivity rates Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study HER2 evaluation and its impact on breast cancer treatment decisions.Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor.Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

P2860

Q24302420-C374D840-AFD8-4FBF-BBE3-6AA5DE4E1D15 Q24792559-BD97292A-2DC9-48E3-A271-CC34EB90184A Q24797752-145460C1-007F-428C-B73E-A95DE607DF38 Q28267134-C04A7BFE-E993-4267-8065-AAA01518E2BE Q28303131-530719A0-1A96-4D6B-B532-264001BE30AB Q28476014-051D153F-87FA-4C27-8853-E2CC1A74FFD0 Q28542825-D3F711F3-EE15-40DB-A560-CBC1F391E422 Q30437453-0ABB9D8B-6DF4-4747-8F48-25DE8AE1FE38 Q30474511-530EF29E-78BC-466B-8A44-015CCA26F236 Q33378811-B7A118C0-38E7-458F-A47C-3208EAFF265B Q33408057-B734E857-D708-4519-822E-6CCF8ACBB1CE Q33699438-2BD9393F-BE97-48D0-8841-671C418AA984 Q33751191-40812575-F822-4094-BA89-F3B3E6C1396A Q33771243-3F556837-8248-4779-8025-D69D1B63A366 Q33863793-18F8F4B9-582B-4894-B746-2DF2ACBB0056 Q33875241-708035B5-7512-4F0C-A0F5-CAD90D524EE6 Q33885989-CD96CD2C-BFBC-4704-980D-E439F0E12393 Q33944976-1BE3830C-CB11-4000-A29F-B4019AEBBC30 Q33991887-3D44269A-0D8E-48C5-85A5-CE727290503E Q34022038-FD27D3B6-AE43-4B4F-9992-EEF7F5E7AD02 Q34071408-17FFED19-A200-40E3-BDB8-B845B7049F8F Q34104079-75F0677D-D40A-4568-A965-9150298AA376 Q34145580-EB8FED30-C0B2-40A5-B376-7F2DDD11802B Q34213855-B41CAD2D-9B43-47E9-AA11-FDAB82509478 Q34371749-B32FAC23-F838-4B2B-A2B7-928B16A5E3A9 Q34424285-2BF344B4-B4E7-4D1B-AE74-CAEA52C3F90B Q34571349-8C763B4F-EC01-42C0-8124-8C67DF40F34F Q34582099-C30F1D09-BC1E-4C4F-9EEA-2D7F56BF6D84 Q34672269-0CC98081-59F5-4062-87D0-9BC9FF38B472 Q34764393-7505D4D2-C76B-4752-AA64-E9CFCEB796B4 Q34855870-BE027D38-75D0-4529-9560-E3586A836EC5 Q34974164-F8076EC3-5717-496F-95A1-476E53158447 Q35078859-6035B7D3-CF04-4DF6-98B4-39A8B47B909C Q35183522-BB13BED5-58D6-4AC3-879D-9149EFD6F7E4 Q35284728-CD6EB160-2F76-4995-AF53-29078D50F563 Q35576343-F3CCA7B1-5699-4316-B9E7-9CBD1BE8FA76 Q35588592-4929010D-C830-457F-B178-42DBAFA036BD Q35589112-6EE68BBB-DE49-416B-9862-8E6A7C3B10F4 Q35776216-89050BFC-A5F0-4CED-9914-98462848385E Q35778406-9B83F713-C385-4E91-B553-BDFFD7992197

P2860

HER-2 testing in breast cancer using parallel tissue-based methods.

http://www.wikidata.org/entity/Q47685189

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

HER-2 testing in breast cancer using parallel tissue-based methods.

@en

HER-2 testing in breast cancer using parallel tissue-based methods.

@nl

type

label

HER-2 testing in breast cancer using parallel tissue-based methods.

@en

HER-2 testing in breast cancer using parallel tissue-based methods.

@nl

prefLabel

HER-2 testing in breast cancer using parallel tissue-based methods.

@en

HER-2 testing in breast cancer using parallel tissue-based methods.

@nl

P1433

Q47685189-1F8B6B3A-5F6F-41A6-ABCA-605031B89685

P1476

Q47685189-DF5029B0-0111-49D1-B99E-1A711687D72D

P2093

Q47685189-093D7BA7-5538-4843-BD87-2CA06CF22CB5

Q47685189-25DE9F3F-FCE6-4AE9-9511-D259AF9A8D5C

Q47685189-4DA1AA56-5F0B-440A-8E29-A7C2AC0BAE7C

Q47685189-5DE39342-48BC-47F5-968D-DD6026555B94

Q47685189-7F0CD37D-4614-41F2-9046-0599918D4CD5

Q47685189-DB8A3ECA-33FB-4B3C-8DD1-F6CC7DE68DF3

Q47685189-DE258F6C-810D-459E-9147-0D874CE20FC0

Q47685189-DF0F8F94-68AE-4ABC-AC7A-1517E075E2A8

Q47685189-FD00C026-3458-482E-806A-DF814D8BA8E7

P304

Q47685189-30DD71A9-8C88-40C8-BC04-4FA7240E90A6

P31

Q47685189-8D2D4DB6-8F92-4772-B4E3-DAC767FB50E5

P356

Q47685189-D58531EF-BCCB-4DD7-B303-C04A61343826

P407

Q47685189-C1280BE3-06AB-48D8-B795-33F793A6B53C

P433

Q47685189-563880B5-CEDE-4B7A-BF29-B1A5AF95495D

P478

Q47685189-8EFD033C-7F2D-4915-B9E9-3B7EB49FDA57

P577

Q47685189-8FAB2312-73E2-4427-8C9E-87BBCBE70EB0

P5875

Q47685189-D4E4F259-5144-4F7D-936C-5C05E73A2723

P698

Q47685189-8C97E630-376C-4C6E-8242-2EE5FC1543CC

P356

JAMA.291.16.1972

P1433

Journal of the American Medical Association

P1476

HER-2 testing in breast cancer using parallel tissue-based methods.

@en

P2093

Allen M Gown

http://www.w3.org/2001/XMLSchema#string

Georgiana K Ellis

http://www.w3.org/2001/XMLSchema#string

Hadi Yaziji

http://www.w3.org/2001/XMLSchema#string

Harry Hwang

http://www.w3.org/2001/XMLSchema#string

Julie R Gralow

http://www.w3.org/2001/XMLSchema#string

Lynn C Goldstein

http://www.w3.org/2001/XMLSchema#string

Robert B Livingston

http://www.w3.org/2001/XMLSchema#string

Robert Werling

http://www.w3.org/2001/XMLSchema#string

Todd S Barry

http://www.w3.org/2001/XMLSchema#string

P304

1972-1977

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.291.16.1972

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

291

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8591073

http://www.w3.org/2001/XMLSchema#string

P698

15113815

http://www.w3.org/2001/XMLSchema#string